Patrick Aloy

Patrick Aloy

Institut de Recerca Biomèdica de Barcelona

Life & Medical Sciences

Dr Patrick Aloy is an ICREA Research Professor and Principal Investigator of the Structural Systems Biology lab at the IRB. He has a BSc in Biochemistry and a MSc in Biotechnology from the Univ. Autònoma de Barcelona, Spain, and spent six years as postdoctoral researcher and staff scientist at the European Molecular Biology Laboratory, Heidelberg, Germany. For twenty years, Dr Aloy has been developing and implementing new technologies and algorithms, applying state-of-the-art methods to specific problems and bridging the gap between theoretical models and experiments in different disciplines. In the last years, he has pioneered system-scale analyses of macromolecular assemblies and networks using high-resolution three-dimensional structures, which has become a new discipline in structure prediction. Dr Aloy has over 120 publications in first-rate journals, with over 13,000 citations and remarkable press coverage, illustrating the scientific and social impact of the work.

Research interests

The main goal of his lab is to combine molecular, cell and computational biology to unveil the basic wiring architecture and dynamics of physio-pathological pathways to increase our understanding of how biological systems change from the healthy state to disease. In the last years he has been developing resources to process, harmonize and integrate bioactivity data on small molecules, providing compound bioactivity descriptors that push the similarity principle beyond chemical properties. Currently, the main research line in the lab is to collect heterogeneous datasets and develop novel methodologies to integrate different layers of regulation to unveil disease signatures. Moreover, they are convinced that artificial intelligence (AI) will transform drug discovery, as it is reshaping other areas of science and technology, and biological signatures are the key to guide the (semi) automated design of chemical compounds to globally revert disease states, beyond individual targets.

Selected publications

- Duran-Frigola M, Pauls E, Guitart-Pla O, Bertoni M, Alcalde V, Amat D, Juan-Blanco T & Aloy P 2020, 'Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker', Nature Biotechnology, 38(9):1087-1096.

- Mateo L, Duran-Frigola M, Gris-Oliver A, Palafox M, Scaltriti M, Razavi P, Chandarlapaty S, Arribas J, Bellet M, Serra V & Aloy P 2020, 'Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns', Genome Medicine, 12, 1, 78.

- Duran-Frigola M, Bertoni M, Blanco R, Martínez V, Pauls E, Alcalde V, Turon G, Villegas N, Fernández-Torras A, Pons C, Mateo L, Guitart-Pla O, Badia-i-Mompel P, Gimeno A, Soler N, Brun-Heath I, Zaragoza H & Aloy P 2020, 'Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs', Journal of Chemical Information and Modeling, 60, 12, 5730–5734.

- Feher C, Plana M, Guardo AC, Climent N, Leal L, Ugarte A, Fernandez I, Etcheverry MF, Gatell JM, Sanchez-Palomino S, Garcia F & Aloy P 2020, 'A Classifier to Predict Viral Control After Antiretroviral Treatment Interruption in Chronic HIV-1-Infected Patients', Jaids-journal Of Acquired Immune Deficiency Syndromes, 83, 5, 479 - 485.

- Luck K, ... , Pons C, ... , Duran-Frigola M, ..., Aloy P, Bader GD, Rivas J, Gaudet S, Hao T, Rak J, Tavernier J, Hill DE, Vidal M & Calderwood F 2020, 'A reference map of the human binary protein interactome', Nature, 580:402-408.

- van Leeuwen J, Pons C, ..., Myers CL, Roth FP, Aloy P, Andrews BJ & Boone C 2020, 'Systematic analysis of bypass suppression of essential genes', Molecular Systems Biology, 16, 9, e9828.

- Mattiazzi Usaj M, Sahin N, Friesen H, Pons C, Usaj M, Masinas MPD, Shuteriqi E, Shkurin A, Aloy P, Morris Q, Boone C & Andrews BJ 2020, 'Systematic genetics and single-cell imaging reveal widespread morphological pleiotropy and cell-to-cell variability', Molecular Systems Biology, 16:e9243.